https://lymphomahub.com

Home | Lymphoma HubOnline lymphoma resource for healthcare professionals, providing information, news & support relating to lymphoma, Hodgkin & non Hodgkin diseaseHome | Lymphoma Hub You need to enable JavaScript to run this app. All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie PolicyYes, I accept cookiesAn expert panel hosted byCustomizing first-line BTK inhibitors for CLLwith Gilles Salles, Paolo Ghia, and Francesc BoschWednesday, October 23, 202418:30-19:30 BSTRegister nowThis independent educational activity is supported by Pharmacyclics LLC, an AbbVie Company and Janssen Biotech. All content is developed independently by the faculty. The funder is allowed no influence on the content of this activity.  TRANSLATEThe Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.Steering CommitteeAbout UsNewsletterContactVisit:ALL HubAML HubGvHD HubLupus HubMPN HubMultiple Myeloma HubPsOPsA HubLOADINGYou're logged in! Click here any time to manage your account or log out.DONATEBrought to you byLOADINGYou're logged in! Click here any time to manage your account or log out.VIEW ALL CONTENTSteering CommitteeAbout UsNewsletterContactDONATESubtypesTherapeuticsCongressesTrialsExpert OpinionsEducational ResourcesDRUG UPDATESVIEW ALLLymphoma & CLL SubtypesAggressive B-cell lymphomasCOVID-19Chronic lymphocytic leukemiasHodgkin lymphomaIndolent B-cell lymphomasMantle cell lymphomasMature T and NK cell neoplasmsRare lymphomasView all MalignanciesVIEW ALL CONTENTAdd bookmarkIACH 2024 live congress feedStay up to date with the latest developments in Lymphoma and CLL from the IACH 2024 Annual Meeting with our live social media coverage.Sep 19, 2024Add bookmarkIbrutinib for CLL: Mechanism of action and clinical considerations We provide an overview of the mechanism of action of ibrutinib and the clinical considerations for the treatment of patients with CLL based on the latest data. Sep 19, 2024Add bookmarkLong-term results from a phase Ib/II study of magrolimab plus rituximab in R/R iNHLWe summarize the 3-year results from a multicenter, phase Ib/II trial investigating the efficacy and safety of magrolimab in combination with rituximab in R/R...Sep 17, 2024Add bookmarkManagement of complications of CAR T-cell therapies in EuropeWe summarize results from a survey by the EBMT designed to assess the management of CAR T-cell complications in patients with ALL, lymphoma, and MM across Europe. Sep 13, 2024Gilles Salles"The Lymphoma Hub allows you to navigate the most relevant and up-to-date information in lymphoma and CLL. From recently published papers to on-site interviews, we aim to deliver valuable data to all physicians practicing hemato-oncology.."Gilles Salles"The Lymphoma Hub allows you to navigate the most relevant and up-to-date information in lymphoma and CLL. From recently published papers to on-site interviews, we aim to deliver valuable data to all physicians practicing hemato-oncology.."Your opinion mattersHCPs, what is your preferred format for educational content on the Lymphoma Hub?Publication summariesVisual abstractsExpert videosExpert podcasts6 votes - 51 days left ...Congressesview moreAdd bookmarkIACH 2024 live congress feedStay up to date with the latest developments in Lymphoma and CLL from the IACH 2024 Annual Meeting with our live social media coverage.Sep 19, 2024Add bookmarkLisocabtagene maraleucel vs standard of care as second-line therapy for LBCL: 3-year follow-up from the phase III TRANSFORM trialWe summarize results from the phase III TRANSFORM trial of liso-cel vs...Sep 5, 2024Add bookmarkSOHO 2024 live congress feedStay up to date with the latest developments in Lymphoma and CLL from the SOHO 2024 Annual Meeting with our live social media coverage.Sep 4, 2024Add bookmarkSymposium | Optimizing outcomes before and after CAR T-cell therapy in patients with large B-cell lymphomaAt the EHA 2024 Hybrid Congress, the Lymphoma Hub and Multiple Myeloma Hub held a joint...Aug 13, 2024Therapeuticsview moreAdd bookmarkIbrutinib for CLL: Mechanism of action and clinical considerations We provide an overview of the mechanism of action of ibrutinib and the clinical considerations for the treatment of patients with...Sep 19, 2024Add bookmarkLong-term results from a phase Ib/II study of magrolimab plus rituximab in R/R iNHLWe summarize the 3-year results from a multicenter, phase Ib/II trial investigating the efficacy and safety of...Sep 17, 2024Add bookmarkManagement of complications of CAR T-cell therapies in EuropeWe summarize results from a survey by the EBMT designed to assess the management of CAR T-cell complications in patients with ALL,...Sep 13, 2024Add bookmarkLisocabtagene maraleucel vs standard of care as second-line therapy for LBCL: 3-year follow-up from the phase III TRANSFORM trialWe summarize results from the phase III TRANSFORM trial of liso-cel vs...Sep 5, 2024Most ReadAdd bookmarkFDA issues new boxed warning for CAR T-cell therapiesAdd bookmarkPET-guided BrECADD for the treatment of advanced-stage cHLAdd bookmarkThe 5th edition of the World Health Organization classification of hematolymphoid tumors: lymphoid neoplasms. Part 1Add bookmarkFrontline ibrutinib for younger patients with MCL: Results from the phase III TRIANGLE trialSupportive careview moreAdd bookmarkIRENE-G: A prospective RCT of nutritional support following allo-HSCTThe Lymphoma Hub is pleased to summarize the design and rationale of the IRENE-G trial (NCT05111834; Impact of Resistance Exercise...Nov 16, 2022Add bookmarkWhat supportive care is needed for patients receiving CAR T-cell therapy?During the 4th European CAR T-cell Meeting, the Lymphoma Hub was pleased to speak with Natacha Bolaños, Lymphoma Coalition,...Feb 26, 2022Treatment of older patients with lymphoma and CLLview moreAdd bookmarkAxi-cel vs chemoimmunotherapy in older patients with R/R LBCLHere, we summarize results from an analysis comparing real-world outcomes of axicabtagene ciloleucel vs chemoimmunotherapy in patients...May 10, 2024Add bookmarkHow to treat older and frail patients with CLL?During the Lymphoma Hub Steering Committee in October 2023, members discussed how to treat older and frail patients with CLL.Dec 4, 2023Add bookmarkHow can we improve care for elderly patients with HL?During the Society of Hematologic Oncology (SOHO) 2023 Congress, the Lymphoma Hub spoke to Jonathan Friedberg, James P. Wilmot Cancer Centre, New...Oct 16, 2023Add bookmarkPOLARIX trial: Is Pola-R-CHP effective and safe in elderly patients with DLBCL?During the 17th ICML, the Lymphoma Hub spoke to Hervé Tilly, Centre Henri-Becquerel and University of Rouen, Rouen, FR....Aug 30, 2023Most ViewedAdd bookmarkPhase III GLOW trial: Ibrutinib plus venetoclax in previously untreated CLL/SLL Add bookmarkSymposium | Optimizing outcomes before and after CAR T-cell therapy in patients with large B-cell lymphomaAdd bookmarkSEQUOIA trial: Zanubrutinib + venetoclax in treatment-naïve patients with CLL/SLL Add bookmarkHow to treat older and frail patients with CLL?Brought to you byDelivering streamlined independent medical education to enhance clinical practiceIn partnership withThank you to the funders of the Lymphoma Hub. All content is developed independently by SES in collaboration with an expert steering committee; funders are allowed no direct influence on the content of the hub.Supported by educational grants from Pfizer, Ipsen Biopharmaceuticals and Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.Interested in becoming a supporter? Please contact us.Terms and ConditionsCookie PolicyPrivacy PolicyNewsletterCopyright ©Lymphoma Hub. 2014-2024. All rights reserved.All content on this site is intended for healthcare professionals only. If you are a patient or carer, please visit the Lymphoma Coalition.enenhttps://lymphomahub.com

Edit your site?

What are you doing?